Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors

J Med Chem. 2005 Mar 10;48(5):1496-505. doi: 10.1021/jm049410e.

Abstract

We present here a dynamic receptor-based pharmacophore model representing the complementary features of the active site region of HIV-1 integrase (IN), which was developed from a series of representative conformations of IN. Conformations of IN were sampled through a molecular dynamics study of the catalytic domain of an IN monomer, and an ensemble of representative IN structures were collected via a probability-based representative conformer sampling method that considers both the potential energy and the structural similarity of the protein conformations. The dynamic pharmacophore model was validated by a set of 128 known inhibitors, and the results showed that over 72% of the active inhibitors (IC(50) lower than 20 microM) could be successfully identified by the dynamic model. Therefore, we screened our in-house database of commercially available compounds against this model and successfully identified a set of structurally novel IN inhibitors. Compounds 7 and 18 with IC(50)s of 8 microM and 15 microM, respectively, against the strand transfer reaction were the most potent. Moreover, 7, 8 and 20 showed a 5-fold selectivity for the strand transfer reaction over 3'-processing.

MeSH terms

  • Binding Sites
  • Catalytic Domain
  • Drug Design
  • HIV Integrase / chemistry*
  • HIV Integrase / genetics
  • HIV Integrase Inhibitors / chemical synthesis
  • HIV Integrase Inhibitors / chemistry*
  • Models, Molecular
  • Molecular Conformation
  • Mutation
  • Probability
  • Protein Conformation
  • Quantitative Structure-Activity Relationship
  • Thermodynamics

Substances

  • HIV Integrase Inhibitors
  • HIV Integrase